Drug Trial Radar · NCT05983250
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
Last checked: Nov 19, 2026Latest source record: Jul 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
230
Planned (sponsor's estimate)
Start
Jan 10, 2024
Primary completion
Jun 30, 2026
Study completion Oct 30, 2028
Sponsor
- Lead sponsor
- Tenax Therapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Medpace, Inc.; Northwestern University
- First posted
- Aug 9, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy of TNX-103 (oral levosimendan) compared with placebo in subjects with PH-HFpEF as measured by the change in 6-Minute Walk Distance (6 MWD; Day 1 to Week 12).
Conditions
- Pulmonary Hypertension
Interventions
TNX-103Drug
oral levosimendan 1 mg
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Six-minute walk distanceTime frame: 12 weeks
Locations
42 sites in 2 countries. Site status is shown where the registry gives one.
Tenax Investigational Site
Tucson, Arizona
Tenax Investigational Site
La Jolla, California
Tenax Investigational Site
Los Angeles, California
Tenax Investigational Site
Los Angeles, California
Tenax Investigational Site
Sacramento, California
Tenax Investigational Site
San Francisco, California
Tenax Investigational Site
Torrance, California
Tenax Investigational Site
Jacksonville, Florida
Tenax Investigational Site
Winter Haven, Florida
Tenax Investigational Site
Atlanta, Georgia
Tenax Investigational Site
Chicago, Illinois
Tenax Investigational Site
Chicago, Illinois
Tenax Investigational Site
Galesburg, Illinois
Tenax Investigational Site
Indianapolis, Indiana
Tenax Investigational Site
Indianapolis, Indiana
Tenax Investigational Site
Louisville, Kentucky
Tenax Investigational Site
Boston, Massachusetts
Tenax Investigational Site
Minneapolis, Minnesota
Tenax Investigational Site
Rochester, Minnesota
Tenax Investigational Site
St Louis, Missouri
Tenax Investigational Site
Omaha, Nebraska
Tenax Investigational Site
New York, New York
Tenax Investigational Site
New York, New York
Tenax Investigational Site
Rochester, New York
Tenax Investigational Site
Roslyn, New York
Tenax Investigational Site
Durham, North Carolina
Tenax Investigational Site
Greensboro, North Carolina
Tenax Investigational Site
Cincinnati, Ohio
Tenax Investigational Site
Columbus, Ohio
Tenax Investigational Site
Pittsburgh, Pennsylvania
Tenax Investigational Site
Providence, Rhode Island
Tenax Investigational Site
Charleston, South Carolina
Tenax Investigational Site
Columbia, South Carolina
Tenax Investigational Site
Dallas, Texas
Tenax Investigational Site
Dallas, Texas
Tenax Investigational Site
Lubbock, Texas
Tenax Investigational Site
Plano, Texas
Tenax Investigational Site
Murray, Utah
Tenax Investigational Site
Richmond, Virginia
Tenax Investigational Site
Madison, Wisconsin
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.